Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Abstract

Abstract BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.

Keywords

• calreticulin mutation
• myelodysplastic/myeloproliferative neoplasms
• plasmacytoid dendritic cell neoplasm
• tumor lysis syndrome